---
title: "Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach."
euct_id: 2024-516756-18-00
phase: Bioequivalence
status: Recruiting
sponsor: Stichting Radboud universitair medisch centrum
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-516756-18-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-516756-18-00"
ctis_last_updated: "2026-05-14T03:33:00.751577514"
source: EU Clinical Trials Information System (CTIS)
---
# Pharmacologically modulating the noradrenergic arousal system to reduce freezing of gait in Parkinson’s disease: a multi-center and multi-modal approach.

**EU CT Number:** [2024-516756-18-00](https://euclinicaltrials.eu/ctis-public/view/2024-516756-18-00)

## Key Facts

- **Phase:** Bioequivalence
- **Status:** Recruiting
- **Sponsor:** Stichting Radboud universitair medisch centrum
- **Start Date:** 2025-07-01
- **Completion Date:** 2026-12-31
- **Conditions:** Parkinson's disease
- **Interventions:** Atomoxetine Aurobindo 40 mg hard capsules, Microcrystalline cellulose gelatin capsule

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (2)

- Radboud Universiteit Nijmegen, Nijmegen, Netherlands
- Radboud universitair medisch centrum Stichting, Nijmegen, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-516756-18-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-516756-18-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-516756-18-00*